In recent years, the tools available for life science researchers have advanced at spectacular speed, and Gladstone pioneered several methods —
consider cellular reprogramming and bioinformatics — that transcend any single disease.
Secondly, before
considering the use of iPSC - derived organoids for transplantation / regenerative medicine in human patients, the current protocols for expansion,
reprogramming and differentiation of iPSCs in long - term cultures need further improvement to minimize the risk of oncogenic
cellular mutations and teratoma, or tumor formation, in the patient.